Where to buy Neoleukin Therapeutics (nltx) stock?
Shares of NLTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Neoleukin Therapeutics' stock price today?
Where can I buy shares of nltx?
Shares of NLTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Does Neoleukin Therapeutics boast high insider ownership?
10.90% of the stock of Neoleukin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. 63.42% of the stock of Neoleukin Therapeutics is held by institutions.
Why did Neoleukin's expenses increase?
The increase in general and administrative expenses was primarily due to increases in personnel-related costs and professional service fees as Neoleukin continues to grow its operations, along with facility related costs associated with the build-out of its new headquarters in Seattle, Washington.
How much cash does Neoleukin have in 2021?
Summary of Financial Results Cash Position: Cash and cash equivalents totaled $178.4 million as of March 31, 2021, compared to $192.6 million as of December 31, 2020. Based upon current internal infrastructure and pipeline initiatives, Neoleukin believes it has sufficient cash to fund operations into 2023.
What is Neoleukin Therapeutics?
A live audio webcast of the corporate presentation and question and answer session to follow will be available from the investors section of the Neoleukin website at http://investor.neoleukin.com/events. An archived replay will also be available on the company website for at least 30 days following the event. About Neoleukin Therapeutics, Inc. Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com. Safe Harbor / Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the therapeutic properties and potential of the company’s de novo protein design technology, the results of the clinical trial for NL-201, and planned clinical and development activities and timelines. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including risks and uncertainties related to the company’s cash forecasts, the company’s ability to advance its product candidates, the receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates, the timing and results of preclinical and clinical trials, the timing of announcements and updates relating to the company’s clinical trials and related data market conditions and further impacts of COVID-19, that could cause actual results to differ materially from what Neoleukin expects. Further information on potential risk factors that could affect Neoleukin’s business and its financial results are detailed under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Contacts: MediaJulie [email protected] InvestorsSolebury TroutAlexandra [email protected]
When will Neoleukin announce its pipeline?
Neoleukin currently plans to announce additional information about its pipeline program during the second half of 2021.
When will Neoleukin start testing?
Neoleukin expects the local administration trial to begin by the end of 2021.
Is Neoleukin a biopharmaceutical company?
SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of new preclinical data on NL-201, an alpha-independent, de novo-designed IL-2 and IL-15 dual agonist, at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021). The presentation highlights preclinical data on NL-201 alone and in seve
Is Neoleukin a public company?
The trial will assess safety, pharmacokinetics, immunogenicity, pharmacodynamics, and antitumor activity. In August 2019, the company went public after a reverse merger with Aquinox Pharmaceuticals, which took a 61.42% stake in the new company in exchange for $65 million in capital for Neoleukin.
